Moderna (MRNA)
(Delayed Data from NSDQ)
$133.40 USD
-1.00 (-0.74%)
Updated Jun 21, 2024 04:00 PM ET
After-Market: $133.32 -0.08 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Moderna, Inc. [MRNA]
Reports for Purchase
Showing records 241 - 256 ( 256 total )
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Yas'' Weekly Recap of Our Key Notes and Upcoming Events
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Part 2: "Must-See" Companies at JPM (Mkt. Cap. $100M-$499M) With 1Q20 Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
As we are three weeks away from JPM Healthcare conference.
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Yas'' Weekly Recap of Our Key Notes and Upcoming Events
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Keeping up with LNP Delivery: Must Read Takeaways from Our Call with Dr.Cullis
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Earnings Recap: Halftime Show of Our Most In-Depth, Differentiated Earnings Yet
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 - Steps On the Gas with Eyes Fixed on CMV - Chikungunya
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
We initiate coverage with a Buy rating and $24/share price target
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y